These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30719874)

  • 1. The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients.
    Basile D; Parnofiello A; Vitale MG; Cortiula F; Gerratana L; Fanotto V; Lisanti C; Pelizzari G; Ongaro E; Bartoletti M; Garattini SK; Andreotti VJ; Bacco A; Iacono D; Bonotto M; Casagrande M; Ermacora P; Puglisi F; Pella N; Fasola G; Aprile G; Cardellino GG
    J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):368-377. PubMed ID: 30719874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
    Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma.
    Wu CH; Liang PC; Hsu CH; Chang FT; Shao YY; Ting-Fang Shih T
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):559-566. PubMed ID: 32651043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Role of Low-Skeletal Muscle Mass on Staging Computed Tomography in Metastasized Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Meyer HJ; Strobel A; Wienke A; Surov A
    Clin Colorectal Cancer; 2022 Sep; 21(3):e213-e225. PubMed ID: 35792019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
    Cushen SJ; Power DG; Murphy KP; McDermott R; Griffin BT; Lim M; Daly L; MacEneaney P; O' Sullivan K; Prado CM; Ryan AM
    Clin Nutr ESPEN; 2016 Jun; 13():e39-e45. PubMed ID: 28531567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma.
    Rollins KE; Tewari N; Ackner A; Awwad A; Madhusudan S; Macdonald IA; Fearon KC; Lobo DN
    Clin Nutr; 2016 Oct; 35(5):1103-9. PubMed ID: 26411749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CT-defined low-skeletal muscle mass as a prognostic marker for survival in prostate cancer: A systematic review and meta-analysis.
    Meyer HJ; Wienke A; Surov A
    Urol Oncol; 2022 Mar; 40(3):103.e9-103.e16. PubMed ID: 34483042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer.
    Lee J; Chang CL; Lin JB; Wu MH; Sun FJ; Jan YT; Hsu SM; Chen YJ
    Clin Cancer Res; 2018 Oct; 24(20):5028-5036. PubMed ID: 29959140
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer.
    Salinas-Miranda E; Deniffel D; Dong X; Healy GM; Khalvati F; O'Kane GM; Knox J; Bathe OF; Baracos VE; Gallinger S; Haider MA
    Eur Radiol; 2021 Nov; 31(11):8662-8670. PubMed ID: 33934171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Western and Eastern criteria for sarcopenia and their association with survival in patients with pancreatic cancer.
    Wu CH; Chang MC; Lyadov VK; Liang PC; Chen CM; Shih TT; Chang YT
    Clin Nutr; 2019 Apr; 38(2):862-869. PubMed ID: 29503056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy.
    Rier HN; Jager A; Sleijfer S; van Rosmalen J; Kock MCJM; Levin MD
    Breast; 2017 Feb; 31():9-15. PubMed ID: 27810702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT-defined sarcopenia predicts treatment response in primary central nervous system lymphomas.
    Surov A; Meyer HJ; Hinnerichs M; Ferraro V; Zeremski V; Mougiakakos D; Saalfeld S; Wienke A; Strobel A; Wolleschak D
    Eur Radiol; 2024 Feb; 34(2):790-796. PubMed ID: 37178198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study.
    Ninomiya G; Fujii T; Yamada S; Yabusaki N; Suzuki K; Iwata N; Kanda M; Hayashi M; Tanaka C; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    Int J Surg; 2017 Mar; 39():45-51. PubMed ID: 28110029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CT assessment of preoperative nutritional status in gastric cancer: severe low skeletal muscle mass and obesity-related low skeletal muscle mass are unfavorable factors of postoperative complications.
    Fang Z; Du F; Shang L; Liu J; Ren F; Liu Y; Wu H; Liu Y; Li P; Li L
    Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):317-324. PubMed ID: 33063547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials.
    Charette N; Vandeputte C; Ameye L; Bogaert CV; Krygier J; Guiot T; Deleporte A; Delaunoit T; Geboes K; Van Laethem JL; Peeters M; Demolin G; Holbrechts S; Flamen P; Paesmans M; Hendlisz A
    BMC Cancer; 2019 Feb; 19(1):134. PubMed ID: 30744591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505.
    Sohal DPS; Boutin RD; Lenchik L; Kim J; Beg MS; Wang-Gillam A; Wade JL; Guthrie KA; Chiorean EG; Ahmad SA; Lowy AM; Philip PA; Chang VT
    J Gastrointest Surg; 2024 Mar; 28(3):232-235. PubMed ID: 38445914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy.
    Kurita Y; Kobayashi N; Tokuhisa M; Goto A; Kubota K; Endo I; Nakajima A; Ichikawa Y
    Pancreatology; 2019 Jan; 19(1):127-135. PubMed ID: 30473464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarcopenia as a Prognostic Marker for Survival in Gastric Cancer Patients Undergoing Palliative Chemotherapy. A Systematic Review and Meta Analysis.
    Meyer HJ; Wienke A; Surov A
    Nutr Cancer; 2022; 74(10):3518-3526. PubMed ID: 35603926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study.
    Maddalena C; Ponsiglione A; Camera L; Santarpia L; Pasanisi F; Bruzzese D; Panico C; Fiore G; Camardella S; Caramia T; Farinaro A; De Placido S; Carlomagno C
    World J Clin Oncol; 2021 May; 12(5):355-366. PubMed ID: 34131567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of low skeletal muscle mass with advanced liver fibrosis in patients with non-alcoholic fatty liver disease.
    Kang MK; Park JG; Lee HJ; Kim MC
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1633-1640. PubMed ID: 30667551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.